Patient Burden Associated With Uncomplicated UTIs

Panelists discuss how patients with recurrent urinary tract infections (UTIs) describe significant burdens including constant anxiety about symptom onset, disruption to work and social life, financial strain from frequent office visits and medications, frustration with treatment-resistant infections, embarrassment discussing symptoms, sexual dysfunction, relationship difficulties, and substantial mental health impacts such as depression and diminished quality of life.

EP: 1.Differentiating Uncomplicated and Complicated Urinary Tract Infections (UTIs)

EP: 2.Trends in Uncomplicated UTIs

EP: 3.Exploring Social Determinants of Health in Uncomplicated UTIs

EP: 4.Examining Uncomplicated UTI Recurrence

EP: 5.Role of Patients’ Education in Uncomplicated UTIs

Now Viewing

EP: 6.Patient Burden Associated With Uncomplicated UTIs

EP: 7.Minimizing Antibiotic Resistance Development in Uncomplicated UTIs

Video content above is prompted by the following:

• How do patients with recurrent UTIs describe the burden of their condition, particularly in relation to treatment resistance, the frequency of office visits, and the impact on their daily lives and mental well-being?

Related Videos

Related Content

Advertisement

March 26th 2025

Speech Recognition Tools May Boost Clinician Documentation Efficiency

Brooke McCormick

Documentation efficiency was higher among younger and male clinicians.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

March 25th 2025

Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer

Brooke McCormick

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) for patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.

Related Content

Advertisement

March 26th 2025

Speech Recognition Tools May Boost Clinician Documentation Efficiency

Brooke McCormick

Documentation efficiency was higher among younger and male clinicians.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

March 25th 2025

Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer

Brooke McCormick

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) for patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.